Regeneron Pharmaceuticals, Inc. XNAS: REGN

Regeneron Pharmaceuticals, Inc. Live Stock Price Today, Share Analysis and Chart

Name: Regeneron Pharmaceuticals, Inc.: Is Infosys Ltd. worth buying?
Item: Regeneron Pharmaceuticals, Inc.
Rating: 2.452194375
Author: Trendlyne DVM scores

Turnaround Potential

about

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet ag...

693.50 -1.49 (-0.21%)

45.54% Gain from 52W Low

906.9K

XNAS Volume

XNAS 14 Nov, 2025 4:30 PM (EST)

Dividend

Regeneron Pharmaceuticals, Inc. has an upcoming dividend of $0.88 per share due on 20 Nov 2025 See details

Medium Financial Strength

44.4 / 100

Mid Valuation

42.7 / 100

Technically Moderately Bullish

64.6 / 100

Turnaround Potential These stocks may be affordable or expensive due to their medium quality and a good technical scoring. However, their reasonable financials successfully attract investors. View Similar Embed DVM

749

1Yr Price target upside is 8%

26 analysts

Regeneron Pharma Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Regeneron Pharmaceuticals, Inc. Live Stock Price Today, Share Analysis and Chart

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet ag...

45.54% Gain from 52W Low

SWOT Analysis

Regeneron Pharma Live Price Chart